Fate Therapeutics Inc
NASDAQ:FATE
Fate Therapeutics Inc
EPS (Diluted)
Fate Therapeutics Inc
EPS (Diluted) Peer Comparison
Competitive EPS (Diluted) Analysis
Latest Figures & CAGR of Competitors
Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Fate Therapeutics Inc
NASDAQ:FATE
|
EPS (Diluted)
-$1
|
CAGR 3-Years
8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-4%
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
0%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
1%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$0
|
CAGR 3-Years
18%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-18%
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$7
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
1%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$13
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$33
|
CAGR 3-Years
-3%
|
CAGR 5-Years
10%
|
CAGR 10-Years
25%
|
See Also
What is Fate Therapeutics Inc's EPS (Diluted)?
EPS (Diluted)
-1.6
USD
Based on the financial report for Dec 31, 2023, Fate Therapeutics Inc's EPS (Diluted) amounts to -1.6 USD.
What is Fate Therapeutics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
-4%
Over the last year, the EPS (Diluted) growth was 44%. The average annual EPS (Diluted) growth rates for Fate Therapeutics Inc have been 8% over the past three years , -7% over the past five years , and -4% over the past ten years .